Abstract
Polycystic ovary syndrome (PCOS) is one of the most common medical conditions in women of reproductive age and the most common cause of anovulatory infertility. Insulin resistance is one of the underpinning features of PCOS in most women. Metformin can improve insulin resistance and was introduced as a pharmacological agent to treat anovulation and infertility in the 1990s. Metformin does not increase ovarian hyperstimulation or multiple pregnancies and may in some clinical situations have a role as a single agent or in combination with clomiphene citrate (CC) however the evidence supports the efficacy of lifestyle intervention as first-line treatment for PCOS anovulatory infertility followed by CC. Here, we discuss the role of metformin in light of other therapies for the treatment of anovulatory infertility in women with PCOS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
